Senti co-founders describe tunable CAR T system

A study led by Senti Biosciences Inc. (South San Francisco, Calif.) Scientific co-Founder Wilson Wong describes a CAR T cell system that uses protein-based linkers to recognize tumor antigens instead of a fixed chimeric antigen receptor, culminating in a more flexible cell therapy that can target multiple antigens. The

Read the full 495 word article

User Sign In